Skip to content

Randomized, Controlled study to Evaluate the Efficacy and Safety of Nasal Spray for Acute Rhinitis

Randomized, Controlled study to Evaluate the Efficacy and Safety of Nasal Spray for Acute Rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025655
Enrollment
Unknown
Registered
2019-09-04
Start date
2018-07-31
Completion date
Unknown
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Rhinitis

Interventions

Experimental:Nasal Spray
Control Group:Physiological Sea Water Nasal Spray

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 63 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-65 years, male or female. 2) In line with the "Guidelines for the Clinical Research of Traditional Chinese Medicine for the Treatment of Intestinal Nasal (Acute Rhinitis), the third series (1997 edition)", the diagnostic criteria for Western medicine, the incidence of intracranial mucosal congestion within 48 hours, the score is greater than 1 point. 3) Voluntary to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Caused by specific inflammations such as allergies, influenza, measles, scarlet fever, and chickenpox. 2) With high heat, the temperature is 38 degree C and above. 3) Patients with bronchitis, bronchitis, sinusitis and other diseases. 4) Patients with serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, and mental patients. 5) severe organic obstruction of the nose (such as nasal septum deviation, nasal polyps or adenoid hypertrophy >= 75%); 6) Pregnant or lactating women and those who cannot be treated as required during the study. 7) Allergic to the test device or the control device. 8) Systematic steroids, antihistamines, intranasal drugs, etc. have been used within 1 week. 9) Participated in other clinical studies within 3 months before the start of the trial. 10) Researchers believe that it is not suitable for participating researchers.

Design outcomes

Primary

MeasureTime frame
rhinoscopy;

Countries

China

Contacts

Public ContactYunying Li

Guangdong Provincial Hospital of Chinese Medicine

gdliyunying@163.com+86 020-81887233-33830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026